These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3051756)

  • 1. [Prolactin--significance in benign and malignant breast diseases].
    Pavić Z; Pavić S
    Z Lymphol; 1988 Jul; 12(1):30-5. PubMed ID: 3051756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The thyroid gland and the breast].
    Pavić Z; Pavić S
    Z Lymphol; 1988 Jul; 12(1):24-9. PubMed ID: 3051755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prolactin in pathology of the breast. Clinical study ].
    Latteri M; Bajardi G; Castiglione C; Caronia F; Maragliano S; Briganti A; Latteri S; Bellanca L
    Minerva Med; 1980 Jul; 71(27):1915-20. PubMed ID: 7393472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum androgen levels and the menstrual cycle in women with benign or malignant breast disease.
    England PC; Sellwood RA; Knyba RE; Irvine JD
    Clin Oncol; 1981 Sep; 7(3):213-9. PubMed ID: 6211319
    [No Abstract]   [Full Text] [Related]  

  • 5. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up.
    Mansour OA; Zekri AR; Harvey J; Teramoto Y; el-Ahmady O
    Anticancer Res; 1997; 17(4B):3101-6. PubMed ID: 9329611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promotion by prolactin of the growth of human breast neoplasms cultured in vitro in the soft agar clonogenic assay.
    Manni A; Wright C; Davis G; Glenn J; Joehl R; Feil P
    Cancer Res; 1986 Apr; 46(4 Pt 1):1669-72. PubMed ID: 3948157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thyroid function and menopausal status in benign and malignant breast diseases].
    Pavić Z; Pavić S
    Med Pregl; 1995; 48(7-8):231-3. PubMed ID: 8524196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Correlations between prolactin and somatotropic hormone in human breast cancer].
    Larrad Jiménez A; Caballero Asensi A; Estévez Molina M
    Rev Esp Oncol; 1980; 27(1):29-52. PubMed ID: 7209107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Proliferative processes in the mammary gland and their significance in tumor development].
    Dubrauszky V; Cura CO
    Gynakol Rundsch; 1970; 10(4):241-67. PubMed ID: 4945696
    [No Abstract]   [Full Text] [Related]  

  • 10. Retrospective assessment of menstrual cycle length in patients with breast cancer, in patients with benign breast disease, and in women without breast disease.
    Olsson H; Landin-Olsson M; Gullberg B
    J Natl Cancer Inst; 1983 Jan; 70(1):17-20. PubMed ID: 6571912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oral contraception and breast pathology.
    Ragni N; Boccardo E; Viglino S; Larosa E
    Acta Eur Fertil; 1981 Jun; 12(2):141-63. PubMed ID: 6794288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of CA-50 radioimmunoassay inhibition test in the differential diagnosis of benign and malignant breast disease.
    Hershman MJ; Habib NA; Kelly SB; Beynon J; Williamson RC; Davies PW; Wood CB
    Eur J Surg Oncol; 1988 Oct; 14(5):413-5. PubMed ID: 3181445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered monocyte function in patients with benign breast disease.
    Al-Sumidaie AM; Leinster SJ; Jenkins SA
    Clin Exp Immunol; 1987 Jan; 67(1):198-204. PubMed ID: 3621673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proceedings: Prolactin in benign and malignant breast disease.
    Cole EN; England PC; Sellwood RA; Griffiths K
    J Endocrinol; 1976 Jun; 69(3):49P-50P. PubMed ID: 950543
    [No Abstract]   [Full Text] [Related]  

  • 15. [Hormonal aspects of benign diseases of the breast].
    Görlich M
    Arch Geschwulstforsch; 1988; 58(5):357-64. PubMed ID: 2849385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolactin does not cause breast cancer and may prevent it or be therapeutic in some conditions.
    Goodman G; Bercovich D
    Med Hypotheses; 2008; 70(2):244-51. PubMed ID: 17658223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prolactin and breast skin temperature rhythms in postmenopausal women with primary breast cancer.
    Wilson DW; Phillips MJ; Holliday HW; Blamey RW; Simpson HW; Pierrepoint CG; Halberg F; Griffiths K
    Chronobiologia; 1983; 10(1):21-30. PubMed ID: 6851763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes in prolactin plasma levels in relation to menopausal status in primary breast carcinoma].
    Pavić S; Pavić Z
    Med Pregl; 1995; 48(5-6):159-61. PubMed ID: 7565335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activators and steroid receptor concentrations in normal, benign, and malignant breast and ovarian tissues.
    Isotalo H; Tryggvason K; Vierikko P; Kauppila A; Vihko R
    Anticancer Res; 1983; 3(5):331-5. PubMed ID: 6685990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Permanent alterations induced in plasma prolactin and estrogen receptor concentration in benign and malignant tissue of women who started oral contraceptive use at an early age.
    Olsson H; Lindahl B; Ranstam J; Borg A; Fernö M; Norgren A
    Anticancer Res; 1987; 7(4B):853-6. PubMed ID: 3674773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.